Skip to Content
  • Article
  • Open Access

1 October 2025

12 Pages

Is the Development of Hypo-Gammaglobulinemia Associated with Better Treatment Response in Patients with Rheumatoid Arthritis Using Rituximab?

,
,
,
,
,
,
,
,
…
1
Division of Rheumatology, Department of Internal Medicine, Ankara University Medical School, 06620 Ankara, Turkey
2
Division of Immunology and Allergy, Department of Internal Medicine, Ankara University Medical School, 06620 Ankara, Turkey
3
Department of Molecular Biology and Genetics, University of Tuebingen, 72074 Tubingen, Germany
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Advances in Clinical Rheumatology

Abstract

Objectives: To determine the frequency of development of hypogammaglobulinemia in rheumatoid arthritis (RA) patients receiving rituximab (RTX) and to examine the relation between the development of hypogammaglobulinemia and RTX treatment response. Methods: The data of 165 RA patients who applied to our outpatient clinic between January 2010 and June 2021, and who received at least 2 courses of RTX with an interval of 6 months, were retrospectively evaluated. The demographic, clinical, and laboratory data, as well as treatment characteristics, were collected. Results: Of 165 patients, 35 (21.2%) developed hypogammaglobulinemia. In the multivariable analysis examining the risk factors for the development of hypogammaglobulinemia in RA patients receiving RTX, it was determined that having pre-treatment IgG value below 10.5 g/l (OR= 4.24 (95% CI 1.69–10.66) and the increase in the number of RTX courses (OR= 1.1 (95% CI 1.01–1.22) were independently associated risk factors. During their follow-up, patients who developed hypogammaglobulinemia and those who did not were compared. No difference was observed between DAS28-ESR levels, but CRP levels were significantly lower in the group that developed hypogammaglobulinemia. Conclusions: In this study, there was no difference in DAS28-ESR levels between patients with and without hypogammaglobulinemia, although a difference was observed in acute phase reactants, which are more objective parameters. This may be due to subjective parameters in DAS28-ESR scoring or other concomitant conditions such as fibromyalgia. Therefore, additional objective findings or methods may guide the evaluation of treatment response.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.